Latest Ratios: P/E Ratio -80.6x · EV/EBITDA N/A · ROE -15.6%. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $211M | $268M | $176M | $112M | $161M | $133M | $252M | $255M | $64M | $48M | $16M |
| Enterprise Value | $206M | $263M | $171M | $105M | $148M | $108M | $225M | $250M | $60M | $44M | $13M |
| P/E Ratio → | -80.56 | — | — | — | — | — | — | 453.47 | 70.51 | 44.17 | — |
| P/S Ratio | 5.14 | 6.52 | 5.24 | 3.93 | 5.76 | 5.67 | 10.44 | 11.01 | 3.70 | 3.00 | 1.31 |
| P/B Ratio | 12.46 | 15.74 | 10.49 | 5.51 | 5.13 | 3.65 | 6.98 | 22.70 | 7.17 | 6.26 | 2.41 |
| P/FCF | — | — | — | — | — | — | — | — | 64.32 | 70.41 | — |
| P/OCF | 456.94 | 580.33 | — | — | — | — | — | 795.55 | 43.40 | 53.33 | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.39 | 5.07 | 3.69 | 5.31 | 4.62 | 9.32 | 10.78 | 3.49 | 2.76 | 1.04 |
| EV / EBITDA | — | — | — | — | — | — | — | 269.55 | 41.04 | 24.56 | — |
| EV / EBIT | — | — | — | — | — | — | 188.98 | 62.37 | 29.31 | 29.66 | — |
| EV / FCF | — | — | — | — | — | — | — | — | 60.57 | 64.58 | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.3% | 60.3% | 63.4% | 58.6% | 55.1% | 58.6% | 61.8% | 64.1% | 62.3% | 59.2% | 61.6% |
| Operating Margin | -7.2% | -7.2% | -19.2% | -36.0% | -38.6% | -29.9% | -5.2% | 2.5% | 6.7% | 9.3% | -6.0% |
| Net Profit Margin | -6.4% | -6.4% | -18.0% | -48.2% | -31.0% | -19.4% | -5.0% | 2.4% | 5.2% | 6.8% | -4.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -15.6% | -15.6% | -32.6% | -53.2% | -25.5% | -12.6% | -5.1% | 5.6% | 11.0% | 15.1% | -8.0% |
| ROA | -9.5% | -9.5% | -21.8% | -38.8% | -20.7% | -11.2% | -4.5% | 4.6% | 9.2% | 12.4% | -6.5% |
| ROIC | -19.5% | -19.5% | -39.4% | -47.9% | -52.8% | -50.6% | -12.7% | 8.0% | 19.6% | 31.5% | -16.3% |
| ROCE | -14.9% | -14.9% | -29.3% | -34.6% | -30.0% | -19.3% | -5.3% | 5.7% | 14.0% | 20.5% | -10.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.21 | 0.21 | 0.24 | 0.22 | 0.16 | 0.02 | 0.01 | 0.03 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | 0.41 | — | — | — |
| Net Debt / Equity | — | -0.32 | -0.33 | -0.35 | -0.40 | -0.68 | -0.75 | -0.49 | -0.42 | -0.52 | -0.50 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | -5.93 | -2.54 | -2.22 | — |
| Debt / FCF | — | — | — | — | — | — | — | — | -3.74 | -5.83 | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | -410.82 |
Net cash position: cash ($9M) exceeds total debt ($3M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.44 | 2.44 | 2.66 | 4.55 | 4.28 | 7.79 | 10.24 | 4.94 | 5.70 | 5.00 | 4.88 |
| Quick Ratio | 1.99 | 1.99 | 2.27 | 3.77 | 3.36 | 6.51 | 8.37 | 3.95 | 4.37 | 3.95 | 3.91 |
| Cash Ratio | 1.08 | 1.08 | 1.33 | 2.58 | 2.50 | 5.29 | 7.45 | 2.44 | 2.36 | 2.67 | 2.57 |
| Asset Turnover | — | 1.46 | 1.24 | 1.00 | 0.66 | 0.57 | 0.61 | 1.67 | 1.65 | 1.72 | 1.50 |
| Inventory Turnover | 4.44 | 4.44 | 4.39 | 3.39 | 1.96 | 1.59 | 1.35 | 3.48 | 3.11 | 3.93 | 3.49 |
| Days Sales Outstanding | — | 57.95 | 65.07 | 51.77 | 46.57 | 55.83 | 38.84 | 50.97 | 29.99 | 42.54 | 49.72 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | 0.2% | 1.4% | 2.3% | — |
| FCF Yield | — | — | — | — | — | — | — | — | 1.6% | 1.4% | — |
| Buyback Yield | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 1.4% | 0.0% | 0.1% | 0.0% | 0.9% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 1.4% | 0.0% | 0.1% | 0.0% | 0.9% |
| Shares Outstanding | — | $46M | $46M | $46M | $45M | $44M | $42M | $39M | $39M | $38M | $38M |
Persistent operating cash burn
Based on reported figures, KRMD trades at a price-to-sales multiple of 4.98, which appears to price in significant future growth expectations that are not currently supported by the company's negative TTM P/E of -78.11 or its lack of positive EBITDA generation.
The current valuation suggests that investors are prioritizing the company's 22.23% revenue growth and its niche market position over immediate earnings. This premium pricing warrants caution, as the market may be overestimating the speed at which the company can transition from an aggressive customer acquisition phase to sustainable profitability.
As reported in recent financial statements, KRMD's ROIC has remained consistently negative, bottoming at -11.4% in 2024Q1 and hovering at -4.3% in 2026Q1, indicating that the company is currently destroying shareholder value rather than compounding it through its ongoing capital investments.
The persistent negative returns on invested capital suggest that the company's heavy investment in sales force expansion and R&D has yet to yield a return that exceeds the cost of capital. Investors should monitor whether the company can achieve a positive ROIC as its installed base of infusion drivers matures and consumable pull-through increases.
According to quarterly data, the cash conversion cycle remains elevated, fluctuating between 81 and 152 days over the last ten quarters, which suggests that KRMD faces structural challenges in managing its inventory and receivables relative to its current revenue growth trajectory.
The high DIO, which reached 131 days in 2023Q4, indicates potential inefficiencies in inventory management or a build-up of stock that may not be moving as quickly as anticipated. This inefficiency ties up critical cash resources, further exacerbating the company's reliance on its existing cash reserves to fund operations.
As reported in recent filings, KRMD's current ratio has tightened from 4.55 in 2023Q4 to 2.33 in 2026Q1, reflecting a narrowing margin of safety as the company continues to burn through its $8.8M cash position to support its ongoing operational and research requirements.
While the current ratio remains above 2.0, the downward trend indicates that the company's liquidity position is becoming more sensitive to operational volatility. Any unexpected disruption in revenue or a delay in pharmaceutical partnerships could necessitate external financing, potentially leading to shareholder dilution.
Investors frequently misapply revenue growth as a proxy for business health, yet this metric obscures the underlying cash burn and lack of operating leverage, as evidenced by the company's 22.23% top-line expansion occurring alongside a -7.23% operating margin.
Relying solely on revenue growth ignores the 'razor-and-blade' model's dependence on long-term consumable pull-through, which is not guaranteed. A more appropriate metric for this business model would be 'consumable pull-through per active placement,' which better captures the durability of the recurring revenue stream than simple top-line growth.
Includes 30+ ratios · 27 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KRMD stock.
KORU Medical Systems, Inc.'s current P/E ratio is -80.6x. The historical average is 23.1x.
KORU Medical Systems, Inc.'s return on equity (ROE) is -15.6%. The historical average is -3.5%.
Based on historical data, KORU Medical Systems, Inc. is trading at a P/E of -80.6x. Compare with industry peers and growth rates for a complete picture.
KORU Medical Systems, Inc. has 60.3% gross margin and -7.2% operating margin.